{"id":33928,"date":"2026-03-17T17:08:23","date_gmt":"2026-03-17T17:08:23","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/33928\/"},"modified":"2026-03-17T17:08:23","modified_gmt":"2026-03-17T17:08:23","slug":"a-look-at-olema-pharmaceuticals-olma-valuation-after-roche-breast-cancer-trial-setback-and-share-price-pullback","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/33928\/","title":{"rendered":"A Look At Olema Pharmaceuticals (OLMA) Valuation After Roche Breast Cancer Trial Setback And Share Price Pullback"},"content":{"rendered":"\n

Get insights on thousands of stocks<\/a> from the global community of over 7 million individual investors at Simply Wall St.<\/p>\n

Olema Pharmaceuticals (OLMA) is back in focus after Roche\u2019s Phase 3 breast cancer trial for giredestrant missed its primary endpoint, a setback that coincided with a sharp 41% drop in Olema\u2019s share price.<\/p>\n

See our latest analysis for Olema Pharmaceuticals.<\/a><\/p>\n

That reaction has not been limited to a single session either. The 7 day share price return is negative 33.91% and the 30 day share price return is negative 36.20% at a last close of US$14.91. At the same time, the 1 year total shareholder return of about 2.4x and the 3 year total shareholder return of just under 3x show how sharp this pullback is compared with a longer period in which investors who stayed in the stock have still seen very large gains overall.<\/p>\n

If this kind of volatility has you looking beyond a single name, it could be a good moment to scan a broader set of breast cancer and oncology names through our focused list of 34 healthcare AI stocks<\/a> as potential research ideas.<\/p>\n

So with Olema now at US$14.91, after a steep pullback but still showing multi year gains, is the market overreacting to a read across from Roche, or already coolly evaluating Olema\u2019s future growth potential?<\/p>\n

On our numbers, Olema looks cheap against an internal fair value estimate but not cheap on its preferred valuation multiple, the P\/B ratio of 3.8x, which is higher than the broader US biotech group.<\/p>\n

The P\/B ratio compares the company\u2019s market value to its net assets on the balance sheet, so it is often used for early stage or unprofitable businesses where earnings do not yet provide a clear anchor. For Olema, that 3.8x figure sits above the US Biotechs industry average of 2.7x. This signals investors are paying a higher price relative to book value than for the sector as a whole.<\/p>\n

At the same time, our SWS DCF model estimates a future cash flow value of $25.49 per share versus the current $14.91 share price. This implies Olema is trading at a meaningful discount to that cash flow based appraisal. The model works by projecting future cash flows and discounting them back to today using a required rate of return, so the output is sensitive to assumptions around revenue growth, timing of potential profitability and reinvestment needs for a clinical stage biotech.<\/p>\n

Put differently, the market price sits above the sector\u2019s average P\/B but below our DCF estimate. Those two signals can reflect very different investor views about long term cash generation versus near term balance sheet value. Our DCF output in this case is also consistent with the separate statement that Olema is trading at 41.5% below our estimate of fair value, which points to a sizable gap between price and that modeled fair value.<\/p>\n

See what the numbers say about this price \u2014 find out in our valuation breakdown.<\/a><\/p>\n

Result: Preferred multiple of price to book at 3.8x (ABOUT RIGHT)<\/p>\n

However, there are clear risk flags, including Olema\u2019s current lack of revenue, its US$149.957 million net loss, and the inherent uncertainty of ongoing clinical trials.<\/p>\n

Find out about the key risks to this Olema Pharmaceuticals narrative.<\/a><\/p>\n

Our SWS DCF model suggests a fair value of $25.49 per share, which is well above the current $14.91 price and indicates that Olema may be trading at a discount. However, with no current revenue, a US$149.957 million loss, and forecasts that keep the company unprofitable over the next 3 years, it is worth considering how comfortable you are relying on long-range cash flow assumptions.<\/p>\n

Look into how the SWS DCF model arrives at its fair value.<\/a><\/p>\n

\"OLMA<\/a> OLMA Discounted Cash Flow as at Mar 2026 <\/p>\n

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Olema Pharmaceuticals for example<\/a>). We show the entire calculation in full. You can track the result in your watchlist<\/a> or portfolio<\/a> and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks<\/a>. If you save a screener<\/a> we even alert you when new companies match – so you never miss a potential opportunity.<\/p>\n

If this mix of risks and potential rewards feels finely balanced, it may be worth taking a closer look now and forming your own view based on 2 key rewards and 4 important warning signs<\/a>.<\/p>\n

If Olema has sharpened your focus, do not stop here. Use this moment to broaden your watchlist and pressure test your thinking across a wider set of opportunities.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include OLMA<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…\n","protected":false},"author":2,"featured_media":24150,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[3632,1104,3542,20071,20072,2354,134,842,1271],"class_list":{"0":"post-33928","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-cash-flow","9":"tag-fair-value","10":"tag-olema","11":"tag-olma","12":"tag-preferred-price","13":"tag-revenue-growth","14":"tag-roche","15":"tag-share-price","16":"tag-total-shareholder-return"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116245620505041196","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/33928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=33928"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/33928\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/24150"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=33928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=33928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=33928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}